Santhera looks to reposition omigapil in congenital muscular dystrophy treatment

17 July 2014

Switzerland-based Santhera Pharmaceuticals (SIX: SAN) has started a clinical program with omigapil, a drug candidate it has in-licensed from Novartis (NOVN: VX) and repositioned for therapeutic use in congenital muscular dystrophy.

Omigapil has previously reached late-stage clinical development for other neurological indications, and Santhera believes it could represent an ideal candidate in treating congenital muscular dystrophy.

This program will be initiated with a Phase I study in congenital muscular dystrophy patients, which will be conducted at the National Institute of Neurological Disorders and Stroke. It is supported financially by the European Union program EndoStem, USA-based Cure CMD, and the Swiss Foundation for Research on Muscle Diseases. Patient enrolment is expected to start later this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK